Mar 12, 2018 • 7:05 am EDT Corbus Pharmaceuticals Reports 2017 Financial Results and Provides Clinical Update
Mar 2, 2018 • 8:00 am EST Corbus Pharmaceuticals to Present at the Cowen & Co. 38th Annual Health Care Conference
Feb 15, 2018 • 7:00 am EST Corbus Pharmaceuticals Announces Publication Demonstrating Lenabasum as First Drug to Stimulate Resolution of Innate Immune Responses in a Clinical Model
Feb 14, 2018 • 7:00 am EST Corbus Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference
Feb 6, 2018 • 8:00 am EST Corbus Pharmaceuticals to Present at the 7th Annual LEERINK Partners Global Healthcare Conference
Jan 30, 2018 • 7:05 am EST Corbus Pharmaceuticals Receives $25 Million Development Award from the Cystic Fibrosis Foundation to Support Phase 2b Clinical Study of Lenabasum
Jan 29, 2018 • 4:05 pm EST Corbus Pharmaceuticals Announces Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary Endpoint
Dec 22, 2017 • 7:05 am EST Corbus Pharmaceuticals Announces Initiation of Phase 2 Study of Anabasum for Treatment of Systemic Lupus Erythematosus
Dec 14, 2017 • 7:35 am EST Corbus Pharmaceuticals Initiates "RESOLVE-1" Phase 3 Study in Systemic Sclerosis
Nov 27, 2017 • 4:05 pm EST Corbus Pharmaceuticals Holdings, Inc. Announces Exercise of Option to Purchase Additional Shares in Public Offering